Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant dimeglumine for prevention of cisplatin-induced nausea and vomiting
CTR20170173Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Complete response rate in overall phase. Started Mar 2017; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on CTR20170173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170173.